For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ARCHIVE
ARCHIVE
- Otsuka HD Places Top Priority on Development of OPC-34712
January 3, 2011
- RG1678 Improves Negative Symptoms of Schizophrenia: Roche
January 3, 2011
- Sawai Asks Kyorin to Explain Why It Turned Down Merger Proposal
January 3, 2011
- Tasigna More Effective Than Glivec: Novartis
January 3, 2011
- Eli Lilly to Differentiate Byetta from Victoza
January 3, 2011
- Novartis' Zometa PIII Data Published in Lancet
January 3, 2011
- Rivaroxaban Peak Sales Expected to Exceed 2 Bil. Euro: Bayer
January 3, 2011
- Seattle Genetics, Millennium Present Positive PII Data on SGN-35 in Hodgkin's Lymphoma
January 3, 2011
- Inavir Ranked No. 1 Both in HP, GP Markets: RepTrack Survey
January 3, 2011
- Otsuka: Aquaretic Agent Samsca for Volume Overload
December 20, 2010
- NPhA Reconfirms Opposition to Point Services
December 20, 2010
- PMDA's Reform Team Proposes Unification of PAFSC's PAC and Committees on Drugs
December 20, 2010
- C. Viehbacher Appointed as New PhRMA Chairman
December 20, 2010
- Sales of Ethical Drugs Down 3.4% in October: Crecon Report
December 20, 2010
- FPMAJ to Draft GL on Supply of Information on Drugs Used Off-Label
December 20, 2010
- New Drugs Make Up For Lipitor Patent Expiration: President Umeda of Pfizer
December 20, 2010
- Daiichi Sankyo Prioritizes 1st-in-Class Drugs in R&D: President Nakayama
December 20, 2010
- AZ's Ticagrelor Obtains EC Approval to Prevent Atherothrombotic Events in ACS
December 20, 2010
- Rifaximin to Drive ASKA's Business: President Yamaguchi
December 20, 2010
- BMS Applies for Additional Indication for SPRYCEL in Japan
December 20, 2010
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…